Effect of Dupilumab on Radiological Remission in Patients with Chronic Rhinosinusitis with Nasal Polyp: A One Step Forward Toward Clinical Remission
Mona Al-Ahmad,Asmaa Ali,Haitham Dawood,Gerges Beshreda
DOI: https://doi.org/10.2147/jaa.s478040
2024-10-22
Journal of Asthma and Allergy
Abstract:Mona Al-Ahmad, 1, 2, &ast Asmaa Ali, 2– 4, &ast Haitham A Dawood, 5 Gerges M Beshreda 6 1 Department of Microbiology, College of Medicine, Kuwait University, Kuwait City, Kuwait; 2 Department of Allergy, Al-Rashed Allergy Center, Ministry of Health, Kuwait City, Kuwait; 3 Department of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, People's Republic of China; 4 Department of Pulmonary Medicine, Abbassia Chest Hospital, Ministry of Health, Cairo, Egypt; 5 Department of Diagnostic Radiology, Faculty of Medicine, Zagazig University, Zagazig, Egypt; 6 Department of Diagnostic Radiology, Faculty of Medicine, Minia University, Minia, Egypt &astThese authors contributed equally to this work Correspondence: Mona Al-Ahmad, Microbiology Department, College of Medicine, Kuwait University, P.O. Box 24923, Safat, Kuwait City, 13110, Kuwait, Tel +965-24636515, Fax +965-25332719, Email Background and Objectives: While achieving complete radiological improvement in patients with nasal polyps is often observed following surgical resection, the impact of biologic therapy, specifically dupilumab, on polyp size is an area of great interest. The objective of this study was to assess the effect of dupilumab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) by assessing nasal polyps using the computed tomography (CT) staging system, Lund–Mackay score (LMS). Methods: A two-year prospective cohort study was conducted on 29 patients diagnosed with CRSwNP and asthma and eligible for dupilumab as an add-on therapy. The study involved comprehensive assessments of patients before biologic initiation and after the study. These assessments included clinical, laboratory, and radiological evaluations. Results: Dupilumab treatment reduces LMS across sinuses (p< 0.001) and improves nasal obstruction (p=0.001). Blood eosinophil count (BEC) predicts persistent sinus obstruction, doubling the likelihood per unit increase (odds ratio: 1.67, p=0.02). BEC levels identify persistent nasal obstruction (AUC: 76%, p=0.04), with a cutoff point above 255.5 cells per microliter, revealing a sensitivity of 100% and a specificity of 42%. The probability of persistent nasal obstruction at the 20th month is 55%, regardless of prior nasal polyp surgery (p=0.41). Conclusion: Dupilumab led to significant radiological improvements in patients with CRSwNP, demonstrating a potential role of radiological remission, irrespective of prior nasal polyp surgery. Additionally, BEC levels may guide the likelihood of persistent nasal obstruction. Keywords: chronic rhinosinusitis with nasal polyps, dupilumab, radiological remission, Lund–Mackay score Chronic rhinosinusitis (CRS) is a common condition that affects 5–28% of the general population worldwide. 1 It significantly burdens healthcare utilization and productivity loss. 2 In adults, CRS is characterized by inflammation of the nose and paranasal sinuses, with two or more symptoms lasting at least three months. 3 These symptoms include nasal blockage, discharge, facial pain, and reduction or loss of smell. 4 Endoscopic or Computed Tomography (CT) scan evidence of abnormalities such as nasal polyps, mucosal changes, or sinus involvement is also necessary. 5 The prevalence of CRS is narrowed down to 3–6% when verified by endoscopy and/or CT scan. 1 CRS is traditionally categorized into two types: chronic rhinosinusitis with nasal polyps (CRSwNP) and without nasal polyps (CRSsNP). CRSwNP is characterized by bilateral, endoscopically visualized polyps in the middle meatus, while CRSsNP lacks visible polyps in the middle meatus, confirmed if necessary following decongestant uses. 6 The CRSwNP phenotype affects approximately 1–2.5% of the population. 1 Many factors might affect the course of CRSwNP, such as age of onset, smoking habits, allergy, asthma, and disease severity. 7 Asthma coexists in 30–70% of CRSwNP patients. 8 However, 10–30% of patients with mild asthma and 70–90% of severe asthma patients suffered from nasal polyps. 9 Despite optimal medical treatment and repeated surgeries, a significant number of CRSwNP patients remain uncontrolled, underscoring the imperative for innovative therapeutic approaches. 10 Initially approved for severe asthma, biologic therapies now emerge as a promising solution for patients with CRSwNP and delivering personalized care. 7,11,12 This therapy employs monoclonal antibodies targeting the type-2 inflammatory pathway by inhibiting agents such as IL-4 receptor (IL-4R), IL-5, an -Abstract Truncated-
immunology,allergy,respiratory system